About Arbutus Biopharma Corp - Company Information, Overview, History and Profile
What does Arbutus Biopharma Corp do?
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
Arbutus Biopharma Corp Management structure
All Gross Remunerations are in USD
Mr. Michael J. McElhaugh
Director, Chief Executive Officer and Interim President
-
2025
Gross Remuneration
Year
Ms. Lindsay Androski
Director, President and Chief Executive Officer
-
2025
Gross Remuneration
Year
Arbutus Biopharma Corp Board of directors
All Gross Remunerations are in USD
Mr. Daniel D. Burgess
Independent Director
-
2025
Gross Remuneration
Year
Mr. James R. Meyers
Independent Director
-
2025
Gross Remuneration
Year
Mr. Keith Manchester, M.D.
Independent Director
-
2025
Gross Remuneration
Year
Mr. Richard C. Henriques, M.B.A.
Independent Director
-
2025
Gross Remuneration
Year
Dr. Frank M. Torti, M.D.
Chairman of the Board
-
2025
Gross Remuneration
Year
Mr. Michael J. McElhaugh
Director, Chief Executive Officer and Interim Pres